Structure-Activity Relationships of Bioengineered Heparin/Heparan Sulfates Produced in Different Bioreactors

by Ha Na Kim, John M. Whitelock, Megan S. Lord
Published 2017-05-01

Can We Produce Heparin/Heparan Sulfate Biomimetics Using “Mother-Nature” as the Gold Standard?

by Brooke L. Farrugia, Megan S. Lord, James Melrose, John M. Whitelock
Published 2015-03-01

A Biomimetic Approach toward Enhancing Angiogenesis: Recombinantly Expressed Domain V of Human Perlecan Is a Bioactive Molecule That Promotes Angiogenesis and Vascularization of Im...

by Xiaoting Lin, Fengying Tang, Shouyuan Jiang, Heba Khamis, Andre Bongers, John M. Whitelock, Megan S. Lord, Jelena Rnjak‐Kovacina
Published 2020-09-01

Cancer Metastasis: The Role of the Extracellular Matrix and the Heparan Sulfate Proteoglycan Perlecan

by Zehra Elgundi, Michael Papanicolaou, Michael Papanicolaou, Gretel Major, Thomas R. Cox, Thomas R. Cox, James Melrose, James Melrose, John M. Whitelock, Brooke L. Farrugia, Brooke L. Farrugia
Published 2020-01-01

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan

by Claire Vennin, Pauline Mélénec, Romain Rouet, Max Nobis, Aurélie S. Cazet, Kendelle J. Murphy, David Herrmann, Daniel A. Reed, Morghan C. Lucas, Sean C. Warren, Zehra Elgundi, Mark Pinese, Gabriella Kalna, Daniel Roden, Monisha Samuel, Anaiis Zaratzian, Shane T. Grey, Andrew Da Silva, Wilfred Leung, Australian Pancreatic Genome Initiative (APGI), Suresh Mathivanan, Yingxiao Wang, Anthony W. Braithwaite, Daniel Christ, Ales Benda, Ashleigh Parkin, Phoebe A. Phillips, John M. Whitelock, Anthony J. Gill, Owen J. Sansom, David R. Croucher, Benjamin L. Parker, Marina Pajic, Jennifer P. Morton, Thomas R. Cox, Paul Timpson
Published 2019-08-01